{"publication_id":"826c8f08-fdc3-46b0-9acd-2f25f81d0d03","screening":{"identified":12,"screened":12,"excluded":0,"included":12,"included_or_retained":12,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"12 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The anti-aging case for immunosenescence interventions, as currently constituted, is incomplete; mechanistic plausibility coexists with mixed or sparse human-RCT evidence.","The curated corpus is dominated by observational cohort designs and mechanistic reviews; no completed, long-term mortality or hard-clinical-endpoint randomized controlled trial (RCT) of immunosenescence-directed therapy appears in the included set. For example, Zhong 2025 describes only the design and protocol of a tai-chi RCT in prefrail older adults, not final efficacy data, leaving the synthesis without a replicated human trial that reports all-cause mortality, incident disability, or confirmed infection endpoints. Consequently, the headline conclusion that 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence' reflects the true state of this curated evidence base rather than an absence of existing trials elsewhere. The absence of such outcome-driven RCTs means the synthesis cannot quantify effect sizes for clinically meaningful endpoints, and any claim linking immunosenescence modulation to improved survival remains unsupported within this corpus.","Several outcome domains are touched by only a single source, precluding internal replication. Frailty-related evidence derives primarily from Zhong 2025 (protocol only) and Lai 2025, which examined transcriptional signatures across a child-to-frailty continuum rather than testing an intervention; no second intervention trial with a frailty endpoint is available for cross-validation. Similarly, the link between immunosenescence and ischemic stroke outcomes rests on Seah 2026 alone, while horticultural-therapy feasibility data come from a single pilot RCT with only Wong 2020 reporting null findings. Single-study domains carry elevated risk of type-I error and cannot be assessed for heterogeneity, leaving the strength of association between senescence biomarkers and these clinical outcomes uncertain.","Additional corpus sources included animal/preclinical evidence; the endpoint scope across the corpus is narrow relative to the clinical breadth of immunosenescence. Most included sources report biomarker-level or transcriptomic outcomes—such as SA-β-gal staining, senescence-associated secretory phenotype (SASP) gene expression, or CD4+ T-cell subset frequencies—rather than hard clinical endpoints (Ioannidis 2005). No study in the curated set reported incident infections, vaccine non-response rates, cancer incidence, or time-to-death as a primary outcome, so the synthesis cannot bridge the gap between observed immunological changes and downstream patient-centered events. Additionally, mechanistic evidence from Aiello 2019 and Park 2026 describes pathways by which senolytic or immunomodulatory agents may attenuate senescent-cell accumulation, yet no corresponding translational trial in this corpus validates those pathways clinically. This mechanism-to-clinic gap means that while biological plausibility is established, the magnitude and durability of any clinical benefit remain unknown.","For immunosenescence, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immunosenescence as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 12 curated reference papers, the evidence base for immunosenescence shows a context-dependent profile. Null findings dominate: contextual other, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The immunosenescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}